A matched-pair analysis comparing whole-brain radiotherapy with and without a stereotactic boost for intracerebral control and overall survival in patients with one to three cerebral metastases

Dirk Rades, Stefan Janssen, Amira Bajrovic, Mai Trong Khoa, Theo Veninga, Steven E. Schild

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Twelve years ago, a randomized trial demonstrated that a radiosurgery boost added to whole-brain radiotherapy (WBRT) improved intracerebral control (IC) in patients with one to three cerebral metastases. Overall survival (OS) was improved only in the subgroup of patients with a single metastasis but not in the entire cohort. The present study compared both regimens in a different scenario outside a randomized trial. Methods: A total of 252 patients with one to three cerebral metastases were included. Eighty-four patients receiving WBRT plus a planned stereotactic boost and 168 patients receiving WBRT alone were individually matched 1:2 for nine factors including fractionation of WBRT, age, gender, performance score, primary tumor, number of cerebral metastases, extracerebral metastases, recursive partitioning analysis class, and time between cancer diagnosis and WBRT. Each group of three patients was required to match for all nine factors. Both groups were compared for IC and OS. Results: IC rates at 6, 12, 18 and 24months were 88, 71, 45 and 22% after WBRT plus stereotactic boost vs. 75, 48, 38 and 22% after WBRT alone (p=0.005). OS rates at 6, 12, 18 and 24months were 76, 53, 32 and 25% after WBRT plus stereotactic boost and 67, 45, 29 and 20% after WBRT alone (p=0.10). In patients with a single lesion, OS rates were also not significantly different (p=0.12). Conclusions: Similar to the previous randomized trial from 2004, this matched-pair study showed that a stereotactic boost in addition to WBRT significantly improved IC but not OS.

Original languageEnglish (US)
Article number69
JournalRadiation Oncology
Volume12
Issue number1
DOIs
StatePublished - Apr 24 2017

Fingerprint

Matched-Pair Analysis
Radiotherapy
Neoplasm Metastasis
Survival
Brain
Survival Rate
Radiosurgery
Neoplasms

Keywords

  • Cerebral metastases
  • Intracerebral control
  • Overall survival
  • Stereotactic boost
  • Whole-brain radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

A matched-pair analysis comparing whole-brain radiotherapy with and without a stereotactic boost for intracerebral control and overall survival in patients with one to three cerebral metastases. / Rades, Dirk; Janssen, Stefan; Bajrovic, Amira; Khoa, Mai Trong; Veninga, Theo; Schild, Steven E.

In: Radiation Oncology, Vol. 12, No. 1, 69, 24.04.2017.

Research output: Contribution to journalArticle

@article{71ef59e39509423ab7d9db5520ae1010,
title = "A matched-pair analysis comparing whole-brain radiotherapy with and without a stereotactic boost for intracerebral control and overall survival in patients with one to three cerebral metastases",
abstract = "Background: Twelve years ago, a randomized trial demonstrated that a radiosurgery boost added to whole-brain radiotherapy (WBRT) improved intracerebral control (IC) in patients with one to three cerebral metastases. Overall survival (OS) was improved only in the subgroup of patients with a single metastasis but not in the entire cohort. The present study compared both regimens in a different scenario outside a randomized trial. Methods: A total of 252 patients with one to three cerebral metastases were included. Eighty-four patients receiving WBRT plus a planned stereotactic boost and 168 patients receiving WBRT alone were individually matched 1:2 for nine factors including fractionation of WBRT, age, gender, performance score, primary tumor, number of cerebral metastases, extracerebral metastases, recursive partitioning analysis class, and time between cancer diagnosis and WBRT. Each group of three patients was required to match for all nine factors. Both groups were compared for IC and OS. Results: IC rates at 6, 12, 18 and 24months were 88, 71, 45 and 22{\%} after WBRT plus stereotactic boost vs. 75, 48, 38 and 22{\%} after WBRT alone (p=0.005). OS rates at 6, 12, 18 and 24months were 76, 53, 32 and 25{\%} after WBRT plus stereotactic boost and 67, 45, 29 and 20{\%} after WBRT alone (p=0.10). In patients with a single lesion, OS rates were also not significantly different (p=0.12). Conclusions: Similar to the previous randomized trial from 2004, this matched-pair study showed that a stereotactic boost in addition to WBRT significantly improved IC but not OS.",
keywords = "Cerebral metastases, Intracerebral control, Overall survival, Stereotactic boost, Whole-brain radiotherapy",
author = "Dirk Rades and Stefan Janssen and Amira Bajrovic and Khoa, {Mai Trong} and Theo Veninga and Schild, {Steven E.}",
year = "2017",
month = "4",
day = "24",
doi = "10.1186/s13014-017-0804-1",
language = "English (US)",
volume = "12",
journal = "Radiation Oncology",
issn = "1748-717X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - A matched-pair analysis comparing whole-brain radiotherapy with and without a stereotactic boost for intracerebral control and overall survival in patients with one to three cerebral metastases

AU - Rades, Dirk

AU - Janssen, Stefan

AU - Bajrovic, Amira

AU - Khoa, Mai Trong

AU - Veninga, Theo

AU - Schild, Steven E.

PY - 2017/4/24

Y1 - 2017/4/24

N2 - Background: Twelve years ago, a randomized trial demonstrated that a radiosurgery boost added to whole-brain radiotherapy (WBRT) improved intracerebral control (IC) in patients with one to three cerebral metastases. Overall survival (OS) was improved only in the subgroup of patients with a single metastasis but not in the entire cohort. The present study compared both regimens in a different scenario outside a randomized trial. Methods: A total of 252 patients with one to three cerebral metastases were included. Eighty-four patients receiving WBRT plus a planned stereotactic boost and 168 patients receiving WBRT alone were individually matched 1:2 for nine factors including fractionation of WBRT, age, gender, performance score, primary tumor, number of cerebral metastases, extracerebral metastases, recursive partitioning analysis class, and time between cancer diagnosis and WBRT. Each group of three patients was required to match for all nine factors. Both groups were compared for IC and OS. Results: IC rates at 6, 12, 18 and 24months were 88, 71, 45 and 22% after WBRT plus stereotactic boost vs. 75, 48, 38 and 22% after WBRT alone (p=0.005). OS rates at 6, 12, 18 and 24months were 76, 53, 32 and 25% after WBRT plus stereotactic boost and 67, 45, 29 and 20% after WBRT alone (p=0.10). In patients with a single lesion, OS rates were also not significantly different (p=0.12). Conclusions: Similar to the previous randomized trial from 2004, this matched-pair study showed that a stereotactic boost in addition to WBRT significantly improved IC but not OS.

AB - Background: Twelve years ago, a randomized trial demonstrated that a radiosurgery boost added to whole-brain radiotherapy (WBRT) improved intracerebral control (IC) in patients with one to three cerebral metastases. Overall survival (OS) was improved only in the subgroup of patients with a single metastasis but not in the entire cohort. The present study compared both regimens in a different scenario outside a randomized trial. Methods: A total of 252 patients with one to three cerebral metastases were included. Eighty-four patients receiving WBRT plus a planned stereotactic boost and 168 patients receiving WBRT alone were individually matched 1:2 for nine factors including fractionation of WBRT, age, gender, performance score, primary tumor, number of cerebral metastases, extracerebral metastases, recursive partitioning analysis class, and time between cancer diagnosis and WBRT. Each group of three patients was required to match for all nine factors. Both groups were compared for IC and OS. Results: IC rates at 6, 12, 18 and 24months were 88, 71, 45 and 22% after WBRT plus stereotactic boost vs. 75, 48, 38 and 22% after WBRT alone (p=0.005). OS rates at 6, 12, 18 and 24months were 76, 53, 32 and 25% after WBRT plus stereotactic boost and 67, 45, 29 and 20% after WBRT alone (p=0.10). In patients with a single lesion, OS rates were also not significantly different (p=0.12). Conclusions: Similar to the previous randomized trial from 2004, this matched-pair study showed that a stereotactic boost in addition to WBRT significantly improved IC but not OS.

KW - Cerebral metastases

KW - Intracerebral control

KW - Overall survival

KW - Stereotactic boost

KW - Whole-brain radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85018551239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018551239&partnerID=8YFLogxK

U2 - 10.1186/s13014-017-0804-1

DO - 10.1186/s13014-017-0804-1

M3 - Article

C2 - 28438175

AN - SCOPUS:85018551239

VL - 12

JO - Radiation Oncology

JF - Radiation Oncology

SN - 1748-717X

IS - 1

M1 - 69

ER -